Radiopharmaceuticals Market Size, Share, and Industry Analysis, By Type (Actinium-225, Lutetium-177, Radium-223, Holmium-166, and Others), By Application (Oncology, Cardiology, and Others), Regional Insights and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

RADIOPHARMACEUTICALS MARKET OVERVIEW

The global Radiopharmaceuticals Market is valued at USD 9.93 Billion in 2026 and is projected to reach USD 19.98 Billion by 2035. It grows at a compound annual growth rate (CAGR) of around 8% from 2026 to 2035.

The radiopharmaceuticals market is advancing as nuclear medicine shifts from conventional diagnostic imaging toward targeted diagnosis, theranostics, and precision radionuclide therapy. Radiopharmaceuticals combine radioactive isotopes with biologically active molecules that selectively accumulate in targeted tissues, supporting disease detection or localized radiation delivery. Oncology represents approximately 72% of the market by application, reflecting expanding use in prostate cancer, neuroendocrine tumors, bone metastases, and other malignancies. Lutetium-177 accounts for an estimated 44% share among the specified isotope categories. Increasing PET imaging capacity, targeted alpha therapy research, improved dosimetry, isotope production investments, and specialized radiopharmacy networks continue strengthening the radiopharmaceuticals market.

The United States radiopharmaceuticals market benefits from an established nuclear medicine infrastructure, extensive PET and SPECT imaging capacity, specialized radiopharmacy distribution networks, academic research centers, and growing integration of theranostics into oncology practice. Adoption is particularly strong in prostate cancer imaging and targeted radionuclide therapy, while cardiac PET and neurological PET applications are expanding clinical utilization. Hospitals increasingly coordinate diagnostic imaging, patient selection, dosimetry, therapy administration, and follow-up imaging through integrated nuclear medicine programs. Continued regulatory activity, manufacturing investment, clinical development of targeted alpha emitters, and expansion of regional radiopharmaceutical production are strengthening access while increasing requirements for trained nuclear medicine professionals and reliable isotope logistics.

KEY FINDINGS

LATEST TRENDS

The radiopharmaceuticals market is increasingly shaped by theranostics, where molecular imaging identifies appropriate patients before targeted radioactive therapy is administered. This approach is particularly influential in prostate cancer and neuroendocrine tumors because the same biological target can support diagnostic imaging and therapeutic intervention. Lutetium-177 represents approximately 44% of the specified isotope segmentation, reflecting established clinical acceptance and expanding interest in targeted beta-emitting treatments. Pharmaceutical developers are simultaneously advancing actinium-225 programs because alpha radiation can deliver highly concentrated energy over a short tissue distance, creating opportunities for difficult-to-treat malignancies.

Another important radiopharmaceuticals market trend is expansion of decentralized PET production, regional radiopharmacy networks, automated synthesis, digital dosimetry, and artificial intelligence-supported molecular imaging. Oncology maintains approximately 72% application share, encouraging investment in PSMA-targeted agents, somatostatin receptor targeting, fibroblast activation protein imaging, and new tumor-specific ligands. Companies are also pursuing longer-lived PET isotopes and improved distribution models that can extend molecular imaging beyond facilities located immediately beside cyclotrons. 

Download Free Sample to learn more about this report

RADIOPHARMACEUTICALS MARKET SEGMENTATION

By Type

• Actinium-225 : Actinium-225 accounts for an estimated 13% share of the specified radiopharmaceuticals market type segmentation. Interest in this alpha-emitting isotope is increasing because targeted alpha particles can produce high-energy radiation across a limited tissue distance, potentially concentrating damage within targeted malignant cells while limiting exposure beyond the immediate treatment area. Pharmaceutical companies are investigating actinium-225 conjugated with PSMA-targeting molecules, antibodies, peptides, and other ligands for precision oncology applications. Prostate cancer is a particularly active development area. 

• Lutetium-177 : Lutetium-177 leads the specified type segmentation with approximately 44% market share. Its position is supported by established therapeutic radiopharmaceutical applications, expanding clinical experience, compatibility with targeted ligands, and growing utilization of theranostic oncology pathways. Lutetium-177 emits beta radiation suitable for targeted treatment and also produces emissions that can support post-treatment imaging and dosimetry. The isotope is particularly important in radioligand therapies addressing prostate cancer and somatostatin receptor-positive neuroendocrine tumors.

• Radium-223 : Radium-223 represents approximately 21% of the specified radiopharmaceuticals market type segmentation. The alpha-emitting isotope has an established role in treating patients with selected forms of metastatic castration-resistant prostate cancer involving symptomatic bone metastases. Its biological behavior allows radium to target areas of increased bone turnover, enabling localized alpha radiation within affected skeletal regions. Clinical familiarity and an established regulatory position support its continuing role in nuclear oncology. Research evaluating treatment sequencing and combinations with systemic oncology medicines also contributes to continued interest. 

• Holmium-166 : Holmium-166 accounts for an estimated 7% share of the specified type segmentation. The isotope is used in specialized therapeutic approaches and has attracted attention for radioembolization because its physical characteristics enable therapeutic radiation delivery alongside imaging and dosimetry capabilities. Holmium-based microspheres can support localized treatment strategies where radiation is delivered directly to selected vascular territories rather than administered as broadly distributed systemic therapy. Its market position remains smaller than lutetium-177 and radium-223 because utilization is concentrated in specialized treatment centers and specific clinical procedures.

• Other : Other radiopharmaceutical types collectively represent approximately 15% of the specified isotope segmentation. This category includes diagnostic and therapeutic radionuclides used across PET, SPECT, neurological imaging, cardiac imaging, endocrine applications, bone imaging, and emerging oncology programs. Fluorine-18 remains important for PET because established radiopharmacy networks can manufacture and distribute multiple F-18-labeled imaging agents. Gallium-68 supports targeted PET imaging, including applications linked to theranostic patient selection. Technetium-based radiopharmaceuticals retain significant diagnostic relevance in conventional nuclear medicine.

By Application

• Oncology : Oncology dominates the radiopharmaceuticals market with approximately 72% application share. Demand is driven by increasing integration of molecular imaging and targeted radionuclide therapy into prostate cancer, neuroendocrine tumor, bone metastasis, and precision oncology pathways. PET radiopharmaceuticals help identify molecular targets, stage disease, evaluate recurrence, and select patients for corresponding targeted treatments. Therapeutic radiopharmaceuticals can then deliver radiation directly to cells expressing specific biological markers. PSMA-targeted prostate cancer programs have accelerated awareness of the theranostic model, while somatostatin receptor targeting remains important for neuroendocrine tumors. 

• Cardiology : Cardiology represents approximately 18% of the radiopharmaceuticals market by application. Nuclear cardiology uses radiopharmaceuticals to assess myocardial perfusion, blood flow, tissue viability, and suspected coronary artery disease. PET myocardial perfusion imaging is gaining attention because newer tracers can improve image quality and support quantitative evaluation of myocardial blood flow. Established SPECT procedures continue to maintain broad clinical use, while PET expansion depends on scanner availability, radiopharmaceutical distribution, reimbursement, and cardiology referral patterns. 

• Other : Other applications account for approximately 10% of the radiopharmaceuticals market. Neurology represents an important component as PET tracers support evaluation of amyloid pathology, tau pathology, cerebral metabolism, and selected neurodegenerative conditions. Radiopharmaceuticals are also used in thyroid assessment, renal imaging, infection and inflammation imaging, pulmonary studies, skeletal imaging, and other functional diagnostic procedures. These applications benefit from nuclear medicine's ability to visualize physiological and biochemical activity rather than relying exclusively on structural changes. 

MARKET DYNAMICS

Driving Factor

Expanding adoption of targeted oncology diagnosis and radionuclide therapy.

Growth of precision oncology is a major driver of the radiopharmaceuticals market because molecular imaging can identify biological targets that conventional anatomical imaging may not characterize with comparable functional specificity. Oncology represents approximately 72% of application demand in this report, demonstrating the importance of cancer-related nuclear medicine. Increasing adoption of PSMA imaging, neuroendocrine tumor imaging, bone-targeting therapies, and theranostic treatment pathways is encouraging hospitals to establish dedicated nuclear medicine programs. Radiopharmaceutical developers are responding by expanding isotope pipelines, ligand discovery, manufacturing capacity, and clinical research. Integration of PET imaging with targeted therapy also supports individualized treatment selection and enables physicians to monitor biological response more precisely.

Driver Impact Analysis*

Restaining Factor

Complex manufacturing, short isotope half-lives, and specialized distribution requirements.

Radiopharmaceutical manufacturing requires controlled isotope production, radiochemical synthesis, sterile processing, quality testing, radiation protection, and precisely timed distribution. These requirements create operational barriers that differ significantly from conventional pharmaceutical supply chains. Several clinically important isotopes have limited useful transportation periods, requiring manufacturing facilities and radiopharmacies to coordinate production directly with patient appointments. North America holds approximately 43% of the market partly because its established nuclear pharmacy and PET infrastructure can support these demanding logistics. Regions with fewer cyclotrons, reactors, qualified production centers, or trained nuclear medicine professionals can experience slower adoption. Equipment investment, regulatory compliance, radioactive waste management, transportation restrictions, and manufacturing interruptions further constrain reliable access.

Restaining Impact Analysis*

Expansion of theranostics and next-generation targeted alpha radiopharmaceuticals

Opportunity

Targeted alpha therapy represents a significant opportunity within the radiopharmaceuticals market because alpha-emitting isotopes can deliver highly localized radiation to targeted malignant cells. Actinium-225 currently represents an estimated 13% of the specified type segmentation, but development activity is expanding as companies investigate PSMA, antibody, peptide, and other tumor-targeting approaches.

The opportunity extends beyond prostate cancer into solid tumors expressing actionable molecular targets. Companion PET imaging can improve patient selection and support a complete theranostic pathway. Investment opportunities therefore include isotope production, chelator chemistry, ligand development, automated manufacturing, treatment planning, dosimetry software, radiopharmacy infrastructure, and specialized distribution. 

Maintaining reliable isotope supply while clinical demand expands.

Challenge

Isotope availability remains a fundamental challenge because radiopharmaceutical production depends on specialized reactors, accelerators, cyclotrons, generators, processing facilities, and technically complex purification systems. Lutetium-177 represents approximately 44% of the specified type market, making dependable production particularly important as therapeutic utilization increases.

Production interruptions can affect treatment scheduling because many radioactive materials cannot be stored like conventional pharmaceuticals. The market must simultaneously expand manufacturing capacity, qualified personnel, transportation networks, quality-control laboratories, and hospital treatment infrastructure. Actinium-225 availability presents another challenge as development programs increase demand for high-purity material. 

• Download Free Sample to learn more about this report

•  

RADIOPHARMACEUTICALS MARKET REGIONAL INSIGHTS

• North America

North America holds approximately 43% of the global radiopharmaceuticals market, making it the leading regional market. The United States represents the primary contributor because of extensive PET infrastructure, nuclear pharmacies, specialized cancer centers, academic research institutions, and established regulatory pathways for molecular imaging and radionuclide therapies. Oncology accounts for approximately 72% of global application demand, and North American treatment centers are important adopters of PSMA imaging and targeted radioligand therapy. Regional companies are expanding manufacturing capacity, distribution networks, software-supported dosimetry, and PET tracer availability. The United States also supports substantial clinical research involving actinium-225, lutetium-177, F-18 tracers, and other targeted agents. 

• Europe

Europe accounts for approximately 27% of the global radiopharmaceuticals market. The region has extensive nuclear medicine expertise, established academic research networks, specialized oncology hospitals, isotope production capabilities, and growing experience with theranostic treatment pathways. Germany, France, Italy, Spain, Switzerland, and the United Kingdom maintain significant molecular imaging and nuclear medicine activity. Lutetium-177 represents approximately 44% of the specified global isotope segmentation, and European treatment centers have contributed substantially to clinical adoption and research involving lutetium-based therapies. Europe also supports development of actinium-225 treatments, personalized dosimetry, automated radiochemistry, and novel PET tracers. Regulatory requirements and country-specific reimbursement structures can produce uneven patient access between markets.

• Asia-Pacific

Asia Pacific represents approximately 20% of the global radiopharmaceuticals market. Expansion is supported by increasing PET/CT installations, cancer diagnosis requirements, hospital infrastructure investment, domestic isotope production, and growing interest in precision oncology. China, Japan, South Korea, Australia, and India represent important markets with differing levels of nuclear medicine maturity. Oncology remains the strongest application opportunity, consistent with its approximately 72% global application share. China is expanding domestic radiopharmaceutical development and production capabilities, while Japan maintains sophisticated nuclear medicine and molecular imaging infrastructure. India presents opportunities through increasing PET accessibility, urban diagnostic networks, nuclear research expertise, and a large patient population. 

• Middle East & Africa

Middle East & Africa accounts for approximately 5% of the global radiopharmaceuticals market. Adoption is concentrated in major tertiary hospitals, specialist oncology institutions, and advanced diagnostic centers. Gulf countries are investing in cancer care, PET/CT equipment, nuclear medicine departments, and precision diagnostic technologies as healthcare systems expand specialized services. South Africa maintains established nuclear medicine capabilities and contributes isotope-related expertise. The region's 5% share remains constrained by uneven infrastructure, limited radiopharmacy coverage, specialist availability, and the logistical complexity associated with short-lived isotopes. Import dependence can create additional scheduling and supply challenges. Opportunities are developing through local cyclotron projects, public healthcare investment, private diagnostic networks, and partnerships with international radiopharmaceutical manufacturers. 

• Rest of the World

Rest of the World represents approximately 5% of the global radiopharmaceuticals market, including developing markets across Latin America and other territories not incorporated into the primary regional categories. Brazil is an important Latin American nuclear medicine market with established PET services and increasing interest in advanced molecular imaging. The region's 5% share reflects comparatively limited radiopharmaceutical manufacturing infrastructure and uneven availability of specialized treatment centers. Partnerships between international radiopharmaceutical developers and regional production or distribution companies are becoming increasingly important for improving tracer access. Oncology provides a major expansion opportunity because targeted PET imaging can support treatment selection and disease management. 

KEY INDUSTRY PLAYERS

Competition in the radiopharmaceuticals market combines established pharmaceutical manufacturers, molecular imaging companies, isotope producers, radiopharmacies, equipment suppliers, and emerging targeted radionuclide therapy developers. Major vendors compete through isotope security, manufacturing networks, clinical pipelines, regulatory approvals, hospital relationships, and targeted ligand technologies. Siemens has extensive PET radiopharmaceutical manufacturing and distribution capabilities, while GE Healthcare combines molecular imaging agents with imaging technologies. Bayer maintains experience with radium-223 and targeted radionuclide development. Lantheus has a strong PET radiodiagnostic presence, while Eli Lilly has expanded its radiopharmaceutical interests. Bracco Imaging participates through molecular imaging businesses. Partnerships increasingly connect isotope producers, biotechnology developers, hospitals, contract manufacturers, and regional distributors.

List Of Top Radiopharmaceuticals Companies

• Bracco Imaging (Italy)
• Bayer (U.S.)
• Mallinckrodt (Ireland)
• Nordion (Canada)
• Triad Isotopes (U.S.)
• Lantheus (U.S.)
• IBA Group (China)
• GE Healthcare (U.K.)
• China Isotope & Radiation (China)
• Jubilant Pharmacy (U.S.)
• Eli Lilly (U.S.)
• Advanced Accelerator Applications (France)
• SIEMENS (Germany)
• Dongcheng (China)
• Nvidia (U.S.)

MARKET LEADERSHIP MATRIX: RADIOPHARMACEUTICALS MARKET

Top 2 Companies with Highest Market Share

• SIEMENS: Holds an estimated 16% market share through extensive PET radiopharmaceutical manufacturing, distribution infrastructure, and molecular imaging presence.

• GE Healthcare: Holds an estimated 13% market share supported by PET radiopharmaceuticals, molecular imaging capabilities, and expanding distribution infrastructure.

LEADER INSIGHTS

• GE HealthCare: Kevin O’Neill, President & CEO of Pharmaceutical Diagnostics, emphasized that the PET radiopharmaceutical market is expanding rapidly as innovative radiotracers, precision care, and targeted therapies increase adoption. He highlighted investment in U.S. manufacturing and final-mile distribution as essential to meeting customer demand, improving supply reliability, and supporting the next generation of precision care products. (Published: October 5, 2026 | Source: https://www.gehealthcare.com/)

• Lantheus: Mary Anne Heino, Chief Executive Officer, stated that advances in imaging and evolving clinical guidelines are identifying more patients who could benefit from targeted radiopharmaceutical therapies. Her comments indicate growing clinical demand for radiopharmaceutical treatment and support Lantheus’ strategy of expanding radiodiagnostic and therapeutic capabilities to address increasing adoption across oncology. (Published: March 2, 2026 | Source: https://investor.lantheus.com/)

• Bayer: Christian Rommel, Executive Vice President and Global Head of Research and Development, highlighted continued investment in precision medicine and molecular imaging as important components of Bayer’s innovation strategy. The company identifies targeted alpha therapy, including actinium-225 programs, as a strategic pillar in precision oncology, reflecting growing opportunities for next-generation radiopharmaceutical technologies in advanced cancer treatment. (Published: April 1, 2026 | Source: https://www.bayer.com/)

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment in the radiopharmaceuticals market is concentrating on isotope manufacturing, radioligand pipelines, radiopharmacy networks, cyclotrons, automated synthesis, dosimetry, and specialized treatment facilities. Actinium-225 represents approximately 13% of the specified type segmentation and offers substantial development potential as targeted alpha therapy pipelines progress. Investors are also targeting lutetium-177 supply security, novel chelators, tumor-specific ligands, PET biomarkers, and contract manufacturing capacity. Vertical integration can provide strategic advantages because control over isotope production, drug manufacturing, quality testing, and distribution reduces supply vulnerability. Additional opportunities exist in digital treatment planning, artificial intelligence-supported PET analysis, automated dose preparation, radiation safety technologies, and regional production networks.

NEW PRODUCT DEVELOPMENT

New product development in the radiopharmaceuticals market increasingly connects diagnostic biomarkers with corresponding therapeutic compounds. Lutetium-177, representing approximately 44% of the specified type segmentation, remains central to radioligand development, while actinium-225 is gaining attention for next-generation targeted alpha therapy. Developers are investigating PSMA, somatostatin receptors, fibroblast activation protein, and additional tumor-associated targets. Diagnostic innovation includes F-18 and Ga-68 PET agents designed to improve disease localization, treatment selection, and biological characterization. Development strategies increasingly consider isotope availability at the earliest stages because commercial scalability depends on dependable radionuclide production. Improved chelators, automated synthesis, patient-specific dosimetry, and digital imaging analysis are strengthening product differentiation.

RECENT DEVELOPMENTS

• October 2026 – GE Healthcare – Acquisition expands United States PET radiopharmaceutical manufacturing and final-mile distribution capabilities. GE Healthcare agreed to acquire SOFIE Biosciences, strengthening F-18 PET manufacturing, distribution capabilities, patient access, and rights associated with the FAPI-74 imaging pipeline.

• May 2026 – Bayer – Pipeline advances multiple actinium-225 candidates targeting prostate and liver cancers. Bayer advanced actinium-225 radiopharmaceutical programs including targeted candidates for advanced prostate and liver cancers, strengthening its targeted alpha radionuclide therapy development strategy.

• May 2026 – Bracco Imaging – Partnership expands advanced PET radiopharmaceutical availability within Brazil's nuclear medicine market. Bracco subsidiary Blue Earth Diagnostics partnered with R2PHARMA to improve Brazilian access to advanced PET radiopharmaceuticals through localized production and distribution capabilities.

• April 2026 – Lantheus – New PYLARIFY formulation strengthens manufacturing efficiency and radiopharmaceutical supply flexibility. Lantheus reported FDA approval of PYLARIFY TruVu, developed to improve manufacturing efficiency and supply flexibility while supporting broader PSMA PET imaging availability.

REPORT COVERAGE

The radiopharmaceuticals market report provides comprehensive analysis of isotope categories, clinical applications, regional performance, competitive positioning, investment opportunities, technological advancements, and strategic industry developments. The study covers actinium-225, lutetium-177, radium-223, holmium-166, and other radiopharmaceuticals across diagnostic and therapeutic applications. Application coverage includes oncology, cardiology, neurological imaging, endocrine disorders, and other nuclear medicine procedures. Regional analysis evaluates North America, Europe, Asia Pacific, Middle East & Africa, and Rest of the World. The report further examines theranostics, PET and SPECT infrastructure, targeted radionuclide therapy, isotope production, radiopharmacy distribution, supply-chain requirements, competitive strategies, partnerships, product innovation, regulatory developments, and emerging investment opportunities.